300381.SHE Guangdong VTR Bio-Tech Co Ltd
- Market cap
- CNY 2.58B
- P/E
- -
- P/B
- 0.97x
- ROE
- 0.2%
- Dividend yield
- 1.90%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300381.SHE undervalued?
Graham numberThe Graham number of Guangdong VTR Bio-Tech Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guangdong VTR Bio-Tech Co Ltd fundamental analysis
No fundamental analysis for Guangdong VTR Bio-Tech Co Ltd yet.
Guangdong VTR Bio-Tech Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guangdong VTR Bio-Tech Co Ltd
Guangdong VTR Bio-Tech Co., Ltd., a biotechnology company, researches, develops, produces, and sells bio-enzyme preparations, biosynthetic products, and plant extracts in the biomanufacturing, agriculture, and animal husbandry industry in China and internationally. The company offers animal nutrition and health, biofuel, detergent, food and beverage, brewing, starch sweetness, bakery, and pulp and paper products, as well as textile enzymes, including acid cellulase, neutral …
Full company profileGuangdong VTR Bio-Tech Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guangdong VTR Bio-Tech Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.51B | 1.50B | 1.77B | 2.05B | 1.91B | 1.89B | 1.17B | 796M | 826M | 832M | 811M |
| Gross Profit | 589M | 607M | 650M | 719M | 726M | 675M | 357M | 337M | 366M | 378M | 358M |
| Operating Income | 136M | 115M | 173M | 193M | 241M | -83.1M | 105M | 15.9M | 30.3M | 123K | 15.9M |
| EBITDA | 294M | 288M | 391M | 416M | 436M | 116M | 263M | 116M | 151M | 113M | 10.7M |
| Net Income | 114M | 80.4M | 114M | 128M | 162M | -119M | 18.2M | -10.7M | 31.1M | -19.8M | 4.94M |
| EPS | 0.30 | 0.20 | 0.28 | 0.30 | 0.35 | -0.24 | 0.04 | -0.02 | 0.06 | -0.04 | 0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 3.21B | 3.85B | 4.80B | 4.52B | 4.67B | 4.48B | 3.17B | 3.09B | 2.95B | 2.92B | 2.82B |
| Total Liabilities | 1.16B | 1.76B | 2.39B | 1.79B | 1.41B | 1.43B | 356M | 360M | 294M | 332M | 242M |
| Shareholders' Equity | 1.90B | 1.94B | 2.14B | 2.47B | 2.98B | 2.79B | 2.71B | 2.61B | 2.61B | 2.55B | 2.53B |
| Cash & Short-term Investments | 229M | 214M | 938M | 217M | 303M | 273M | 1.56B | 1.23B | 799M | 416M | 454M |
| Total Debt | 726M | 1.09B | 1.84B | 1.05B | 769M | 844M | 152M | 74.4M | 35.0M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -44.1M | -4.37M | 204M | 442M | 404M | 217M | 250M | 154M | 69.2M | 121M | - |
| Capital Expenditure | 338M | 349M | 311M | 398M | 283M | 163M | 198M | 394M | 377M | 277M | 226M |
| Free Cash Flow | -382M | -354M | -107M | 44.3M | 121M | 54.0M | 52.0M | -240M | -308M | -156M | -153M |
| Ratios | |||||||||||
| ROE | 6.0% | 4.1% | 5.3% | 5.2% | 5.4% | -4.3% | 0.7% | -0.4% | 1.2% | -0.8% | 0.2% |
| ROA | 3.5% | 2.1% | 2.4% | 2.8% | 3.5% | -2.7% | 0.6% | -0.3% | 1.1% | -0.7% | 0.2% |
| Net Profit Margin | 7.5% | 5.4% | 6.4% | 6.2% | 8.4% | -6.3% | 1.6% | -1.4% | 3.8% | -2.4% | 0.6% |
| Debt to Equity | 0.38x | 0.56x | 0.86x | 0.43x | 0.26x | 0.30x | 0.06x | 0.03x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guangdong VTR Bio-Tech Co Ltd dividends
- Dividend yield
- 1.90%
- Forward dividend
- 0.05 CNY
- Payout ratio
- -
- Ex-dividend date
- Jun 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 49.1M | 0.10 | - |
| 2024 | CNY 34.6M | 0.07 | 111.1% |
| 2023 | CNY 51.1M | 0.10 | - |
| 2022 | CNY 49.0M | 0.10 | 268.8% |
| 2021 | CNY 34.3M | 0.07 | - |
| 2020 | CNY 28.6M | 0.06 | 17.7% |
| 2019 | CNY 24.4M | 0.06 | 19.1% |
| 2018 | CNY 100M | 0.25 | 88.4% |
| 2017 | CNY 70.1M | 0.17 | 87.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 30:10 on Oct 18, 2016.
Who owns Guangdong VTR Bio-Tech Co Ltd
- Insiders 41.80%
- Institutions 2.34%
- Public & others 55.86%
- Shares outstanding 480M
- Free float 309M
Guangdong VTR Bio-Tech Co Ltd company profile
- Company name
- Guangdong VTR Bio-Tech Co Ltd
- Ticker
- 300381.SHE
- ISIN
- CNE100001RJ8
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,106
- Fiscal year end
- December
- Address
- No. 8, Pingbei 1st Road, Zhuhai, China, 519060
- Phone
- 86 75 6867 6888
- Website
- vtrbiotech.com
About Guangdong VTR Bio-Tech Co Ltd
Guangdong VTR Bio-Tech Co., Ltd., a biotechnology company, researches, develops, produces, and sells bio-enzyme preparations, biosynthetic products, and plant extracts in the biomanufacturing, agriculture, and animal husbandry industry in China and internationally. The company offers animal nutrition and health, biofuel, detergent, food and beverage, brewing, starch sweetness, bakery, and pulp and paper products, as well as textile enzymes, including acid cellulase, neutral cellulase, catalase, alkaline protease, medium temperature desizing enzyme, etc. It provides Boluohui Extract, a veterinary drug raw material and powder; and other biotechnology solutions. The company also exports its products. Guangdong VTR Bio-Tech Co., Ltd. was founded in 1991 and is based in Zhuhai, China.
Guangdong VTR Bio-Tech Co Ltd management
10- Mr. Derong ZhouPresident & Director · born 1968
- Mr. Xiaoping HuangFinancial Director & Head of Accounting Department · born 1985
- Mr. Guancheng ChenVP & Director · born 1991
- Ms. Shanmin ZhuSecretary · born 1985
- Mr. Shiliang DingAssistant to President · born 1966
- Mr. Guohua FengVice President · born 1970
- Mr. Hongfang DuVice President · born 1976
- Mr. Binfeng ZhuangVice President · born 1981
- Mr. Yangyuan LiVP and Director of R&D Center · born 1983
- Ms. Xichun PuAccounting Supervisor · born 1980